LOS ANGELES--(BUSINESS WIRE)--May 25, 2006--Abraxis BioScience, Inc. (NASDAQ:ABBI - News), an integrated, global biopharmaceutical company, today named its executive committee and seven officers to its executive management team: Richard E. Maroun as chief administrative officer; Thomas H. Silberg as executive vice president, commercial operations & operational excellence; John F. Weidenbruch as general counsel and assistant corporate secretary; Bruce Wendel as executive vice president, corporate development; and Ronald E. Pauli as interim chief financial officer. Frank Harmon, as announced in a separate release, has joined the company as executive vice president, global operations. Nicole S. Williams, who has served as chief financial officer and president of the Abraxis Pharmaceutical Products (APP) division, will retire from APP to pursue other opportunities. Carlo Montagner continues as President of Abraxis Oncology. These seven executives will form the Executive Committee of Abraxis BioScience.
